Hypertonic Saline and Furosemide Reduce Inflammation in Acute Heart Failure

A randomized controlled trial has found that combining intravenous furosemide with small-volume hypertonic saline solution (HSS) significantly reduces inflammatory and remodeling markers in patients suffering from acute decompensated heart failure (ADHF). The study suggests that this combination therapy may modulate the pathophysiological environment of the failing heart at a molecular level, specifically affecting epigenetic signatures.

The research was led by Mario Daidone and Antonino Tuttolomondo at the University Hospital Policlinico Paolo Giaccone and the University of Palermo. The findings focus on patients with ADHF attributable to heart failure with reduced ejection fraction (HFrEF), a life-threatening condition where impaired left ventricular function and systemic congestion lead to a sudden worsening of symptoms.

Study Design and Methodology

The trial enrolled 200 subjects with ADHF. These participants were randomly assigned into two distinct treatment groups to compare the efficacy of the combined approach against the standard of care.

One group received standard intravenous furosemide therapy, a loop diuretic used to relieve fluid overload. The second group received intravenous furosemide combined with small volumes of hypertonic saline solution.

Researchers evaluated the patients at three specific intervals: at admission (T0), after treatment (T1), and after a saline bolus (T2). The evaluation focused on serum concentrations of several biomarkers and specific microRNA (miRNA) concentrations to determine the treatment’s impact on inflammation and cardiac remodeling.

Impact on Biomarkers and Epigenetics

The results indicated that the combination of i.v. Furosemide and HSS led to a significant decrease in the serum levels of several key markers. These include:

• NT-proBNP
• hsTnT
• s-ST2
• galectin-3
• IL-6 (Interleukin-6)
• CRP (C-reactive protein)

At the T1 evaluation point, patients treated with high-dose furosemide plus HSS exhibited higher absolute delta values for IL-6, hsTnT, NT-proBNP, and galectin-3. Those receiving the combined therapy showed significantly lower increases in these serum concentrations following a saline load at T2.

Beyond inflammatory markers, the study observed changes in epigenetic regulators. Specifically, there was a decrease in the expression of miR181b in subjects treated with the combination of i.v. Furosemide and HSS compared to those who received furosemide alone. The reduction of miRNA181b expression was more significant in the combined therapy group.

Medical Context and Clinical Implications

Loop diuretics like furosemide are the standard treatment for managing fluid overload in heart failure patients. However, the long-term effects of these diuretics on inflammation, cardiac remodeling, and epigenetic regulation have previously remained elusive.

The use of hypertonic saline solution as an adjunct therapy is intended to modulate the molecular environment of the heart. Some existing research has suggested that combining furosemide with HSS could protect renal function, which in turn increases the diuretic effect and benefits the patient.

Despite these findings, the broader efficacy of HSS combined with furosemide in treating acute heart failure remains a subject of controversy in the medical community. While this trial demonstrates a reduction in remodeling and inflammatory markers, the overall clinical application continues to be explored.

The modulation of miRNA expression is particularly noteworthy, as these molecules serve as critical epigenetic regulators of gene expression, potentially influencing how the heart remodels itself during and after a failure event.